Zanubrutinib (BioDeep_00000858855)
代谢物信息卡片
化学式: C27H29N5O3 (471.2270284)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C=CC(=O)N1CCC(CC1)C2CCNC3=C(C(=NN23)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=O)N
InChI: InChI=1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)/t22-/m0/s1
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163774 - BTK-targeting Agent
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
D000970 - Antineoplastic Agents
D006401 - Hematologic Agents
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- KEGGdrug: D11422
- PubChem: 135565884
- DrugBank: DB15035
- ChEMBL: CHEMBL3936761
- CAS: 1691249-45-2
- CAS: 1651179-04-2
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Xiaohe Li, Yuli Wei, Shimeng Li, Jingjing Liang, Zhichao Liu, Yunyao Cui, Jingjing Gao, Zhongyi Yang, Lei Li, Honggang Zhou, Shanshan Chen, Cheng Yang. Zanubrutinib ameliorates lipopolysaccharide-induced acute lung injury via regulating macrophage polarization.
International immunopharmacology.
2022 Oct; 111(?):109138. doi:
10.1016/j.intimp.2022.109138. [PMID: 35973369] - Chunhua Ma, Qingyun Li, Minghao Zhao, Goujie Fan, Jie Zhao, Dandan Zhang, Shouning Yang, Shuting Zhang, Dingding Gao, Longfei Mao, Liang Zhu, Wei Li, Guiqing Xu, Yuqin Jiang, Qingjie Ding. Discovery of 1-Amino-1H-imidazole-5-carboxamide Derivatives as Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitors.
Journal of medicinal chemistry.
2021 11; 64(21):16242-16270. doi:
10.1021/acs.jmedchem.1c01559. [PMID: 34672559] - Ying C Ou, Zhiyu Tang, William Novotny, Aileen Cohen, Kun Wang, Lucy Liu, Yuying Gao, Srikumar Sahasranaman. Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma.
Leukemia & lymphoma.
2021 11; 62(11):2612-2624. doi:
10.1080/10428194.2021.1929961. [PMID: 34159878] - Ying C Ou, Zhiyu Tang, William Novotny, Manal Tawashi, Ta-Kai Li, Hugh A Coleman, Srikumar Sahasranaman. Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP.
British journal of clinical pharmacology.
2021 07; 87(7):2926-2936. doi:
10.1111/bcp.14707. [PMID: 33336408] - Satyavani Kaliamurthi, Gurudeeban Selvaraj, Chandrabose Selvaraj, Sanjeev Kumar Singh, Dong-Qing Wei, Gilles H Peslherbe. Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19.
International journal of molecular sciences.
2021 Jun; 22(13):. doi:
10.3390/ijms22137071. [PMID: 34209188] - H Yesid Estupiñán, Qing Wang, Anna Berglöf, Gerard C P Schaafsma, Yuye Shi, Litao Zhou, Dara K Mohammad, Liang Yu, Mauno Vihinen, Rula Zain, C I Edvard Smith. BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.
Leukemia.
2021 05; 35(5):1317-1329. doi:
10.1038/s41375-021-01123-6. [PMID: 33526860] - Kun Wang, Xueting Yao, Miao Zhang, Dongyang Liu, Yuying Gao, Srikumar Sahasranaman, Ying C Ou. Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator.
CPT: pharmacometrics & systems pharmacology.
2021 05; 10(5):441-454. doi:
10.1002/psp4.12605. [PMID: 33687157] - Ying C Ou, Lucy Liu, Bilal Tariq, Kun Wang, Ashutosh Jindal, Zhiyu Tang, Yuying Gao, Srikumar Sahasranaman. Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B-Cell Malignancies.
Clinical and translational science.
2021 03; 14(2):764-772. doi:
10.1111/cts.12948. [PMID: 33306268] - Elise A Chong, Lindsey E Roeker, Mazyar Shadman, Matthew S Davids, Stephen J Schuster, Anthony R Mato. BTK Inhibitors in Cancer Patients with COVID-19: 'The Winner Will be the One Who Controls That Chaos' (Napoleon Bonaparte).
Clinical cancer research : an official journal of the American Association for Cancer Research.
2020 07; 26(14):3514-3516. doi:
10.1158/1078-0432.ccr-20-1427. [PMID: 32345646] - Gasim Dobie, Fahd A Kuriri, Musab M A Omar, Fehaid Alanazi, Ali M Gazwani, Chloe P S Tang, Daniel Man-Yuen Sze, Sasanka M Handunnetti, Constantine Tam, Denise E Jackson. Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin αIIbβ3 in mice and humans.
Blood advances.
2019 12; 3(24):4298-4311. doi:
10.1182/bloodadvances.2019000640. [PMID: 31869418] - Viola Denzinger, Kristina Busygina, Janina Jamasbi, Isabell Pekrul, Michael Spannagl, Christian Weber, Reinhard Lorenz, Wolfgang Siess. Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib.
Thrombosis and haemostasis.
2019 Mar; 119(3):397-406. doi:
10.1055/s-0039-1677744. [PMID: 30685871]